SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-475551"
 

Search: onr:"swepub:oai:DiVA.org:uu-475551" > Poor outcome after ...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Poor outcome after systemic therapy in secondary high-grade pancreatic neuroendocrine tumors

Mollazadegan, Kazhan (author)
Uppsala universitet,Endokrin tumörbiologi
Skogseid, Britt (author)
Uppsala universitet,Endokrin tumörbiologi
Botling, Johan (author)
Uppsala universitet,Klinisk och experimentell patologi
show more...
Åkerström, Tobias (author)
Uppsala universitet,Endokrinkirurgi
Eriksson, Barbro (author)
Uppsala universitet,Endokrin tumörbiologi
Welin, Staffan (author)
Uppsala universitet,Onkologisk endokrinologi
Sundin, Anders, 1954- (author)
Uppsala universitet,Radiologi
Crona, Joakim (author)
Uppsala universitet,Endokrin tumörbiologi
show less...
 (creator_code:org_t)
Bioscientifica, 2022
2022
English.
In: Endocrine Connections. - : Bioscientifica. - 2049-3614. ; 11:3
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Longitudinal changes in pancreatic neuroendocrine tumor (panNET) cell proliferation correlate with fast disease progression and poor prognosis. The optimal treatment strategy for secondary panNET grade (G)3 that has progressed from a previous low- or intermediate-grade to high-grade panNET G3 is currently unknown. This was a single-center retrospective cohort study aimed to characterize treatment patterns and outcomes among patients with secondary panNET-G3. Radiological responses were assessed using the Response Evaluation Criteria in Solid Tumors version 1.1. A total of 22 patients were included and received a median of 2 (range, 1–4) treatment lines in 14 different combinations. Median overall survival (OS) was 9 months (interquartile range (IQR): 4.25–17.5). For the 15 patients who received platinum–etoposide chemotherapy, median OS was 7.5 months (IQR: 3.75–10) and median progression-free survival (PFS) was 4 months (IQR: 2.5–5.5). The 15 patients who received conventional panNET therapies achieved a median OS of 8 months (IQR: 5–16.75) and median PFS was 5.5 months (IQR: 2.75–8.25). We observed one partial response on 177Lu DOTA-TATE therapy. In conclusion, this hypothesis-generating study failed to identify any promising treatment alternatives for patients with secondary panNET-G3. This demonstrates the need for both improved biological understanding of this particular NET entity and for designing prospective studies to further assess its treatment in larger patient cohorts.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kirurgi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Surgery (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Keyword

pancreatic neuroendocrine tumor
highgrade
systemic therapy
treatment outcomes

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view